martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 12, 2026

SK Hynix Joins the Nasdaq. But This Nasdaq-100 Semiconductor Stock Could Be an Even Better Buy for the Second Half of 2026.

View original at nasdaq.com
SK Hynix Joins the Nasdaq. But This Nasdaq-100 Semiconductor Stock Could Be an Even Better Buy for the Second Half of 2026. Key Points The memory chip shortage is one of the biggest bottlenecks for artificial intelligence (AI)…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Stock Advisor's total average return is 929%, a market-crushing outperformance compared to 211% for the S&P 500.

    60% confidence
  • In Q1 2026, memory's share of ASML net system sales rose to 51% (from 42% in Q1 2025), while logic's share fell to 49% (from 58% in Q1 2025).

    60% confidence
  • ASML is an even better Nasdaq-100 stock than SK Hynix for investors seeking a fundamental AI stock to buy and hold for at least five years.

    60% confidence
  • ASML is the better buy for folks with a long-term investing time horizon compared to memory stocks like SK Hynix.

    60% confidence
  • ASML has a virtual monopoly on extreme ultraviolet (EUV) machines.

    60% confidence
  • Demand for SK Hynix memory chips is far outpacing supply, creating a multi-year runway for future growth that has propelled the company to a $1 trillion valuation.

    60% confidence
  • SK Hynix will never join the S&P 500 because it is a South Korean company, similar to Taiwan Semiconductor Manufacturing.

    60% confidence
  • ASML doesn't design or manufacture chips; it produces advanced machines needed to perform the lithography step in semiconductor manufacturing.

    60% confidence

Data points we hold from this source

Applied Materials, Inc. · forward pe ratio49.2 ratio
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com